Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Rhabdomyosarcoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 10Irinotecan 8Cyclophosphamide 7dinutuximab 5aldesleukin 4Interleukin-2 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3fludarabine 3Topotecan 3Melphalan 3Isotretinoin 3Filgrastim 3gallium Ga 68 dotatate 2Vincristine 2TPI-287 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Carboplatin 2venetoclax 1trametinib 1thymoglobulin 1talazoparib 1sonidegib 1silmitasertib 1plerixafor 1olaparib 1naxitamab 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroblastoma × adavosertib × Clear all
NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
76 enrolled 25 charts
CNSSarcoma

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡